Nuvectis Pharma, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Nuvectis Pharma, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$27.57M	-$19.85M	-$22.90M	-$19.23M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$26.44M	-$19.00M	-$22.26M	-$19.09M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.32	$-1.11	$-1.43	$-1.51
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.32	$-1.11	$-1.43	$-1.51

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$31.60M	$18.50M	$19.10M	$20.00M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$31.71M	$18.61M	$19.18M	$20.41M
Everything the company owes — debt, unpaid bills, and other obligations.	$13.30M	$8.89M	$6.98M	$6.19M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$18.41M	$9.71M	$12.20M	$14.22M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$16.01M	-$12.25M	-$15.95M	-$13.56M